Bionomics to Present BNC210 at Society for Neuroscience

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bionomics to Present BNC210 at Society for Neuroscience Meeting

ADELAIDE, Australia, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) is presenting a poster on anti-anxiety compound BNC210 at the Neuroscience 2014 conference being held by the Society for Neuroscience (SFN) in Washington DC.

Bionomics' poster, The novel anxiolytic compound BNC210 is a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor , shows BNC210 is a specific antagonist of the alpha7 nicotinic acetylcholine receptor with effectiveness displayed in both humans and rodents. The poster outlines the experiments performed to demonstrate that the anxiolytic effect of BNC210 is produced by negative allosteric modulation of the alpha 7 nicotinic acetylcholine receptor.

The poster will be part of session number 321 titled Mood Disorders: Novel Therapeutic Mechanisms , from 8am-12pm today at the Walter E. Washington Convention Center.

BNC210 is a small molecule discovered by Bionomics that is in development for the treatment of anxiety disorders. Data from several preclinical studies indicated it may have anti-anxiety activity and appeared to promote neurite outgrowth in vitro. It is free of benzodiazepine-like side effects and in a CCK-4-induced panic model in healthy volunteers it substantially reduced the number and intensity of panic symptoms and helped subjects recover more quickly.

To date BNC210 has been evaluated in 148 healthy volunteers and has proven to be safe and well tolerated. On 11 November 2014 Bionomics announced that it had received approval for a Phase Ib clinical trial to be conducted in France by Biotrial International, in which healthy volunteers will receive multiple ascending doses of BNC210 and target engagement will be examined. This trial is anticipated to commence in Q1, 2015. Bionomics has also submitted a Phase II clinical trial application in the UK. Pending approval this trial is anticipated to commence in 1H, 2015.

SFN is the world's largest organisation of scientists and physicians devoted to the study of the brain and nervous system. Founded in 1969 it has over 40,000 members with 130 chapters worldwide.

About Bionomics Limited

Bionomics (ASX:BNO) is a biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

Bionomics Limited Dr Deborah Rathjen CEO & Managing Director +618 8354 6101 / 0418 160 425 Monsoon Communications Rudi Michelson +613 9620 3333 The Trout Group Lauren Glaser +1 646 378 2972

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 188

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 227

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 62

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 60

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 117

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 112

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 89

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 83

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

UGREEN's NAS Launch: Is AI the Game-Changer or Just Hype?

Updated Category News Views 227

UGREEN announced its flagship AI NAS models on February 17, 2026, aiming to redefine private cloud data management with an active approach. Traders perked up when they heard about the iDX Series—specifically the UGREEN NASync iDX6011 and its Pro version. But here's where you should be asking tough questions: Can UGREEN really deliver amidst a crowded tech space? The...

Continue Reading
LRT Company Introduces $17 Million Senior Living Investment Deal

Updated Category News Views 133

LRT Company Unveils Innovative Senior Living Project In a significant move for the senior living sector, LRT Company has rolled out the LRT Hardeeville Senior Living DST. This cash-based offering aims to generate $17 million from accredited investors and presents a compelling opportunity to meet the growing demand for quality senior housing. Offering Details The LRT...

Continue Reading
Innovative Advances in Dendritic Cell Therapies for Cancer

Updated Category News Views 287

Groundbreaking Insights in Cancer Immunotherapy In an exciting development, Northwest Biotherapeutics (OTCQB: NWBO) plans to showcase significant advancements at the upcoming Frontiers in Cancer Immunotherapy Conference. Dr. Marnix Bosch, the company's Chief Technical Officer, will present a discussion titled "Next Generation Dendritic Cell Treatments to Improve...

Continue Reading
Scooter's Coffee: Celebrated among Leading US Franchises

Updated Category News Views 303

Scooter's Coffee Receives Esteemed Recognition in Franchise Rankings With over 850 locations spread across multiple states, Scooter's Coffee has secured a prominent position as one of the leading drive-thru coffee brands in the United States. The brand has been recognized for its impressive growth and community engagement, establishing itself as a favorite among coffee...

Continue Reading
Viatris Investors Urged to Act – Important Legal Deadline Approaches

Updated Category News Views 355

Viatris Class Action Lawsuit Updates Kahn Swick & Foti, LLC offers a timely reminder to investors who have suffered losses exceeding $100,000 in Viatris Inc. (NASDAQ: VTRS). The firm urges affected individuals to take note of the approaching deadline for lead plaintiff applications in light of the ongoing securities class action lawsuit involving the company....

Continue Reading